부산대학교 도서관

Clinical usefulness of measurement of serum concentration of the pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP) was evaluated for diagnosing of bone metastasis in patients with prostate cancer.A total 34 patients, i.e., 17 with benign prostatic hyperplasia (BPH), 10 with prostate cancer without bone metastasis, 7 with prostate cancer with bone metastasis, served as the subjects of this study. The serum level of ICTP was significantly higher in prostate cancer patients with bone metastasis (5.3-13.2; mean 8.7±3.2ng/ml) than in patients with either BPH (1.0-5.9; mean 3.1±1.4ng/ml) or prostate cancer without bone metastasis (1.9-4.9; mean 3.4±1.0ng/ml). In 5 of 7 patients with prostate cancer and bone metastasis, serum ICTP level and bone scintigram were examined after 3 months of endocrine therapy. In all patients, decrease of serum ICTP level and clinical response to treatment on scintigram were observed.Serum ICTP should be useful marker in diagnosing and monitoring bone metastasis in patient with prostate cancer.